Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2013
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical featuresFortunato Morabito, Laura Mosca, Giovanna Cutrona, et al.
Cancers|June 29, 2019
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12Francesco Autore, Paolo Strati, Idanna Innocenti, et al.
Cancer|May 19, 2023
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20)Simone Oerlemans, Fabio Efficace, Charalampia Kyriakou, et al.
Cancers|July 2, 2021
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibFrancesca Romana Mauro, Diana Giannarelli, Andrea Visentin, et al.
American Journal of Hematology|October 10, 2012
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemiaSonia Fabris, Laura Mosca, Giovanna Cutrona, et al.
American Journal of Hematology|April 5, 2013
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Sonia Fabris, et al.
Oncotarget|May 29, 2018
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphomaAlessandro Broccoli, Beatrice Casadei, Alice Morigi, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
American Journal of Hematology|January 14, 2014
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Ilaria Del Giudice, Antonio Cuneo, et al.
Pageof 16